See today's BioWorld
To read the full story, subscribe or sign in.

With hold lifted, Fulcrum restarts phase Ib of FTX-6058 in sickle cell disease

Aug. 22, 2023
By Karen Carey
Shares of Fulcrum Therapeutics Inc. shot up 38.5% on Aug. 22 following news that the U.S. FDA had lifted the clinical hold on the company’s phase Ib sickle cell disease candidate, FTX-6058.
BioWorld Clinical Regulatory Hematologic FDA